drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Proposed biosimilar of daratumumab; an anti-CD38 human IgG1κ monoclonal antibody (IV) that binds CD38 on malignant plasma cells, inducing ADCC, CDC, antibody-dependent phagocytosis, and direct apoptosis; inhibits CD38 ectoenzyme activity and reduces CD38+ immunosuppressive cells, potentially enhancing T-cell–mediated antitumor activity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD38 human IgG1κ monoclonal antibody that binds CD38 on malignant plasma cells, triggering ADCC, CDC, and antibody-dependent phagocytosis and inducing direct apoptosis; also inhibits CD38 ectoenzyme activity and depletes CD38+ immunosuppressive cells, enhancing T-cell–mediated antitumor responses.
drug_name
BCD-264
nct_id_drug_ref
NCT06296121